IMW 2019 | Serum BCMA: a new prognostic marker for PFS in myeloma

James Berenson

James Berenson, MD, from The Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, speaks at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, about monitoring serum BCMA levels to indicate prognosis in multiple myeloma.

Share this video